Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Lake Street starts Profound Medical at Buy; PT $16.50

Lake Street initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $16.50 price target. The stock closed at $10.19 on July 22. Analyst Ben Haynor writes that with reimbursement of TULSA...

July 23, 2024

Developments

Cytel unveiled as alliance partner with OneMedNet

Closely-held Cytel, a global leader in clinical trial design and software, announced today its strategic partnership with OneMedNet (NASDAQ:ONMD) to enhance data-driven healthcare solutions. The partnership will...

July 22, 2024

Developments

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...

July 22, 2024

Executive Moves

Sernova appoints Jonathan Rigby as executive chairman

Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) has named Jonathan Rigby as executive chairman, effective immediately. Mr. Rigby, previously a director with the company, replaces chairman Brett Whalen, who has resigned...

July 18, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Markets

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

After market close today, Stifel upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “buy” from “hold” and raised its price target to $12 from $9 in response to the U.S. Centers for Medicare and Medicaid Services (CMS)...

July 15, 2024

Markets

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

July 15, 2024

Markets

Raymond James upgrades Alpha Cognition to outperform; PT to $2

Raymond James upgraded Alpha Cognition (CSE:ACOG) to “outperform” from “market perform” and raised its price target to C$2 from C$1 with the company’s PDUFA date less than 2 weeks away (July 27th). The stock closed at...

July 15, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Developments

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Rainhouse Manufacturing Canada, a well-established North American CNC machining and manufacturing company, emphasized a recent CNN interview with Dr. Sanjay Gupta, which uncovered the real cause of weight-loss drug...

July 12, 2024

Developments

Remembering Elias Vamvakas, a friend and mentor

For the first time since we began publishing in 2009, the BioTuesdays family is lost for words, almost. With devastating sadness, we learned today of Elias Vamvakas’ passing. A pioneering entrepreneur in the Canadian...

July 11, 2024

Lake Street starts Profound Medical at Buy; PT $16.50

Cytel unveiled as alliance partner with OneMedNet

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Sernova appoints Jonathan Rigby as executive chairman

Clearmind files additional U.S. patent application for MEAI to treat obesity

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

Raymond James upgrades Alpha Cognition to outperform; PT to $2

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Remembering Elias Vamvakas, a friend and mentor

General

More